Therapeutic Uses of Rituximab and Clinical Features in Immunoglobulin G4-Related Disease: A Systematic Review

Abstract

This research presents a systematic review focusing on rituximab's therapeutic applications in immunoglobulin G4 (IgG4)-related disease (IgG4-RD), a rare condition characterized by immune-mediated systemic inflammation and tissue fibrosis, as well as the clinical features of IgG4-RD. While the disease commonly affects organs such as the bile ducts, lymph nodes, retroperitoneum, pancreas, and salivary glands, it can potentially involve other organs. This intricacy often leads to diagnostic challenges due to clinical overlaps with cancer, infections, and other autoimmune disorders. The diagnosis of IgG4-RD necessitates a comprehensive approach involving laboratory tests, imaging studies, and clinical assessments. Symptoms can vary, ranging from lymphadenopathy to jaundice, affecting multiple organs. Although elevated blood IgG4 levels and findings of tissue involvement and fibrosis on imaging can be suggestive, they lack the specificity for a definitive diagnosis. Early diagnosis is crucial for initiating corticosteroids and immunosuppressive to prevent further damage from IgG4-RD. This study highlights the therapeutic role of rituximab in managing this condition. Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria, the research identifies and evaluates relevant literature across various electronic databases, including PubMed, ScienceDirect, and Google Scholar. This review includes 14 selected publications, comprising three systematic reviews, three observational studies, four narrative reviews, and four case reports. The study design ensures a comprehensive evaluation of rituximab's potential efficacy in treating IgG4-RD and its associated clinical characteristics. Based on this study, it can be concluded that IgG4-RD can potentially be treated with rituximab, particularly in cases of relapse and maintaining remission.

Clinical Features, Differential Diagnosis and Treatment of IgG₄-Related Sclerosing Cholangitis

“…Ретроспективный анализ, сравнивающий циклофосфамид и микофенолат, не продемонстрировал превосходства одного препарата над другим с точки зрения индукции ремиссии [66]. Ритуксимаб использовали для индукции и поддержания ремиссии при наличии противопоказаний к приему ГКС и стероидсберегающих препаратов, а также при неэффективности указанных лекарственных средств [67,68]. Согласно результатам мета-анализа, полный ответ через 6 месяцев наблюдался у 88,9 % (95 % ДИ 80.5-93.9), частота рецидивов составила 21 % (95 % ДИ 10,5-40,3), медиана времени до рецидива составила 10 месяцев [67].…”